ArticleCancer immunology, immunotherapy : CII2026
Downregulation of ANKRD22 promotes ovarian cancer cell proliferation by enhancing the immunosuppressive capacity of M-MDSCs.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
ANKRD22 is a protein involved in tumor immune regulation. To elucidate its role in ovarian cancer, we analyzed its expression pattern and association with the tumor immune microenvironment. Bioinformatics analyses revealed upregulation of ANKRD22 in ovarian cancer tissues compared with normal controls. High ANKRD22 expression correlated with favorable patient prognosis, suggesting its potential as a prognostic biomarker. In vitro experiments using the ID8 murine ovarian cancer cell line, selected for its relevance to immunocompetent mouse models in tumor microenvironment studies, revealed that ANKRD22 expression is regulated by the tumor microenvironment. Monocytic myeloid-derived suppressor cells (M-MDSCs) with Ankrd22 knockout exhibited enhanced immunosuppressive function, inhibited T lymphocyte proliferation and reduced IL-2 secretion. These M-MDSCs promoted ovarian cancer cell proliferation primarily through direct contact. RNA sequencing suggested that Ankrd22 might regulate the immunosuppressive function of M-MDSCs by modulating fatty acid metabolism. In vivo rescue experiments in a subcutaneous tumor model confirmed that Ankrd22 mediates the protumor effect of M-MDSCs. In summary, this study demonstrated that downregulation of ANKRD22 promotes ovarian cancer progression by enhancing the immunosuppressive function of M-MDSCs, providing a theoretical basis for targeting ANKRD22 in ovarian cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.